Kiora Pharmaceuticals (KPRX) Stock Price, News & Analysis

Company Overview

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Key Stats

• Today's Range: $2.98 to $3.17
• 50-Day Range: $2.95 to $4.03
• 52-Week Range: $2.91 to $6.48
• Volume: 9,441 shs
• Average Volume: 32,737 shs
• Market Capitalization: $9.06 million
• P/E Ratio: 2.90
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Strong Buy

Kiora Pharmaceuticals Stock Analysis - MarketRank™

Kiora Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Kiora Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Kiora Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Kiora Pharmaceuticals are expected to decrease in the coming year, from $1.28 to ($2.76) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kiora Pharmaceuticals is 2.90, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.78.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kiora Pharmaceuticals is 2.90, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.14.

Price to Book Value per Share Ratio

Kiora Pharmaceuticals has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.95% of the float of Kiora Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Kiora Pharmaceuticals has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kiora Pharmaceuticals has recently increased by 7.91%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kiora Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Kiora Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.95% of the float of Kiora Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Kiora Pharmaceuticals has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kiora Pharmaceuticals has recently increased by 7.91%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.0 / 5
• News Sentiment: -0.22

News Sentiment

Kiora Pharmaceuticals has a news sentiment score of -0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Kiora Pharmaceuticals this week, compared to 0 articles on an average week.

MarketBeat Follows

Only 1 people have added Kiora Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kiora Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.94% of the stock of Kiora Pharmaceuticals is held by insiders.

Percentage Held by Institutions

76.97% of the stock of Kiora Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

KPRX Stock Analysis - Frequently Asked Questions

How have KPRX shares performed this year?

Kiora Pharmaceuticals' stock was trading at $3.30 at the start of the year. Since then, KPRX stock has decreased by 8.5% and is now trading at $3.02.
View the best growth stocks for 2025 here.

How were Kiora Pharmaceuticals' earnings last quarter?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) posted its earnings results on Tuesday, March, 25th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by $0.40. The business earned $0.75 million during the quarter, compared to analysts' expectations of $0.75 million.

When did Kiora Pharmaceuticals' stock split?

Kiora Pharmaceuticals shares reverse split on the morning of Tuesday, June 11th 2024. The 1-9 reverse split was announced on Tuesday, June 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 11th 2024. An investor that had 100 shares of stock prior to the reverse split would have 11 shares after the split.

Who are Kiora Pharmaceuticals' major shareholders?

Kiora Pharmaceuticals' top institutional shareholders include Rosalind Advisors Inc. (8.35%), Rosalind Advisors Inc. (8.35%) and ADAR1 Capital Management LLC (6.67%). Insiders that own company stock include Brian M Strem, Eric Joseph Daniels, Erin Parsons, Melissa Tosca, Aron Shapiro and Lisa Walters-Hoffert.
View institutional ownership trends.

How do I buy shares of Kiora Pharmaceuticals?

Shares of KPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Kiora Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kiora Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 3/25/2025
• Today: 3/27/2025
• Next Earnings (Estimated): 5/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KPRX
• CIK: 1372514
• Web: eyegatepharma.com
• Phone: (781) 788-9043
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $10.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +231.1%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $1.04
• Trailing P/E Ratio: 2.90
• Forward P/E Ratio: 2.36
• P/E Growth: N/A
• Net Income: $-12,510,000.00
• Net Margins: N/A
• Pretax Margin: 35.21%
• Return on Equity: 21.32%
• Return on Assets: 16.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.97
• Quick Ratio: 8.97

Sales & Book Value

• Annual Sales: $16 million
• Price / Sales: 0.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.14 per share
• Price / Book: 0.42

Miscellaneous

• Outstanding Shares: 3,001,000
• Free Float: 2,973,000
• Market Cap: $9.06 million
• Optionable: Not Optionable
• Beta: -0.46